For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Nafarelin acetate - Transgender Health - adults
PAD Profile : Nafarelin acetate - Transgender Health - adults
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Testosterone
- Triptorelin
- Goserelin acetate
- Leuprorelin acetate
- Medroxyprogesterone acetate
- Estradiol
- Ethinylestradiol
- Cyproterone acetate
- Finasteride
Other Indications
Additional Documents
Committee Recommendations
After undertaking a review of previous decisions and resources relating to transgender health, the APC agreed an AMBER status for oestrogen, testosterone, cyproterone, finasteride, GnRH & medroxyprogeterone when used in adults.
Primary care initiation of these drugs is supported by the APC if the prescriber is competent to exercise their share of clinical responsibility and is assured that the shared care protocol provides enough information for them to discharge their responsibilities safely.
A guide to support primary care prescribing for people who access gender identity services was also agreed by the APC.
The guide includes information on children and young people, requests to prescribe, shared care, on-going care and private providers.
The Surrey Heartlands Integrated Care System Area Prescribing Committee have reviewed the traffic light status' of treatments used for transgender health in adults.
Nafarelin (Nasal Spray) has been given an AMBER traffic light status.